ReviewPharmaceutics2023
Exosomes: Potential Next-Generation Nanocarriers for the Therapy of Inflammatory Diseases.
Review in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Nanoparticles for autoimmune diseases: advancing diagnostics and therapeutic solutions.Acta pharmacologica Sinica · 2026Review
- Nanomedicine targeting neuroinflammatory pathways in Alzheimer's disease: a new frontier in inflammopharmacology.Inflammopharmacology · 2026Review
- Fine structural tuning of the assembly of elastin-collagen peptide conjugates with drug loading and manipulation of molecular interactions.Biomaterials science · 2026Article
- Exosomes as Disease-Informed Nanoplatforms for Pulmonary Fibrosis: From Pathogenic Signaling to Precision Diagnosis and Therapy.Pharmaceutics · 2026Review
- Exosomes-loaded with traditional Chinese medicine constituents: a novel therapeutic avenue for aplastic anemia.Chinese medicine · 2026Review
- Nanotechnology-Based Modulation of Autoimmune Microenvironments in Sjögren's Syndrome: A Review of Mechanistic Perspectives.International journal of nanomedicine · 2026Review
- Molecular mechanisms and translational potential of plant-derived nanovesicles in skin care and regeneration.Frontiers in cell and developmental biology · 2026Review
- Mechanism of action behind the pain-relief effects of extracellular vesicles in microfragmented adipose tissue: an in vitro and in vivo study.Journal of translational medicine · 2025Article
- Childhood Asthma Biomarkers Derived from Plasma and Saliva Exosomal miRNAs.International journal of molecular sciences · 2025Article
- Pathophysiological Mechanisms of Diabetes-Induced Macrovascular and Microvascular Complications: The Role of Oxidative Stress.Medical sciences (Basel, Switzerland) · 2025Review
- Article
- Potential and challenges of utilizing exosomes in osteoarthritis therapy (Review).International journal of molecular medicine · 2025Review
- Recent Progress in Nano-TCM Active Ingredient Co-Delivery Systems for Inflammation-Mediated Diseases.International journal of nanomedicine · 2025Review
- Milk-Derived Extracellular Vesicles: A Novel Perspective on Comparative Therapeutics and Targeted Nanocarrier Application.Vaccines · 2024Review
- Extracellular vesicles and their content in the context of polycystic ovarian syndrome and endometriosis: a review.Journal of ovarian research · 2024Review
- Leveraging high-throughput screening technologies in targeted mRNA delivery.Materials today. Bio · 2024Review
- Exosome-Mediated Antigen Delivery: Unveiling Novel Strategies in Viral Infection Control and Vaccine Design.Vaccines · 2024Review
- Delivery Strategies for Colchicine as a Critical Dose Drug: Reducing Toxicity and Enhancing Efficacy.Pharmaceutics · 2024Review
- Extracellular Vesicles: Novel Potential Therapeutic Agents in Inflammatory Bowel Diseases.Cells · 2023Review
- HMGB1 Carried by Small Extracellular Vesicles Potentially Plays a Role in Promoting Acquired Middle Ear Cholesteatoma.Diagnostics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Inflammatory diseases are common pathological processes caused by various acute and chronic factors, and some of them are autoimmune diseases. Exosomes are fundamental extracellular vesicles secreted by almost all cells, which contain a series of constituents, i.e., cytoskeletal and cytosolic proteins (actin, tubulin, and histones), nucleic acids (mRNA, miRNA, and DNA), lipids (diacylglycerophosphates, cholesterol, sphingomyelin, and ceramide), and other bioactive components (cytokines, signal transduction proteins, enzymes, antigen presentation and membrane transport/fusion molecules, and adhesion molecules). This review will be a synopsis of the knowledge on the contribution of exosomes from different cell sources as possible therapeutic agents against inflammation, focusing on several inflammatory diseases, neurological diseases, rheumatoid arthritis and osteoarthritis, intestinal bowel disease, asthma, and liver and kidney injuries. Current knowledge indicates that the role of exosomes in the therapy of inflammation and in inflammatory diseases could be distinctive. The main limitations to their clinical translation are still production, isolation, and storage. Additionally, there is an urgent need to personalize the treatments in terms of the selection of exosomes; their dosages and routes of administration; and a deeper knowledge about their biodistribution, type and incidence of adverse events, and long-term effects of exosomes. In conclusion, exosomes can be a very promising next-generation therapeutic option, superior to synthetic nanocarriers and cell therapy, and can represent a new strategy of effective, safe, versatile, and selective delivery systems in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.